Insider Selling: Nektar Therapeutics (NASDAQ:NKTR) CEO Sells $30,087.64 in Stock

Nektar Therapeutics (NASDAQ:NKTR) CEO Howard Robin sold 418 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $71.98, for a total transaction of $30,087.64. Following the completion of the transaction, the chief executive officer directly owned 54,627 shares of the company’s stock, valued at $3,932,051.46. The trade was a 0.76% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Nektar Therapeutics Trading Down 0.7%

NASDAQ:NKTR opened at $74.02 on Friday. Nektar Therapeutics has a 12-month low of $26.45 and a 12-month high of $109.00. The firm has a market cap of $2.53 billion, a price-to-earnings ratio of -11.05 and a beta of 1.14. The company’s 50-day moving average is $69.63 and its two-hundred day moving average is $70.36.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($1.23) EPS for the quarter, topping analysts’ consensus estimates of ($1.97) by $0.74. The business had revenue of $10.13 million during the quarter, compared to the consensus estimate of $10.43 million. Nektar Therapeutics had a negative net margin of 287.84% and a negative return on equity of 37.87%. On average, equities research analysts forecast that Nektar Therapeutics will post -8.6 earnings per share for the current fiscal year.

Key Nektar Therapeutics News

Here are the key news stories impacting Nektar Therapeutics this week:

• Positive Sentiment: Nektar’s latest quarterly results included an adjusted loss of $1.23 per share, substantially better than the $1.97 analyst consensus. The earnings-call transcript provides additional management commentary on the company’s pipeline and financial outlook. Nektar Q2 2026 Earnings Call Transcript
• Positive Sentiment: Institutional ownership remains high at approximately 75.9%, while several funds—including AQR Capital Management, Two Seas Capital and Armistice Capital—recently increased their positions. The broader analyst consensus is still “Moderate Buy,” with an average price target well above the current trading level. Nektar institutional ownership and analyst ratings
• Neutral Sentiment: JPMorgan initiated coverage with a “Neutral” rating and a $65 price target. The target is below the recent share price, signaling limited near-term upside in JPMorgan’s view, although the rating is not an outright sell recommendation. JPMorgan initiates coverage of Nektar
• Neutral Sentiment: CEO Howard Robin and insider Jonathan Zalevsky sold shares to cover tax withholding obligations tied to vested equity awards. The transactions were relatively small compared with their remaining holdings, reducing their significance as a bearish signal. Nektar insider transactions
• Negative Sentiment: Revenue of $10.13 million fell slightly short of the $10.43 million estimate, while Nektar continues to report substantial losses and is expected to post approximately negative $8.60 in full-year EPS. HC Wainwright also issued a negative outlook for NKTR earnings, adding to concerns about ongoing cash burn and execution risk. HC Wainwright earnings outlook

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. BNP Paribas Financial Markets increased its stake in Nektar Therapeutics by 93.8% during the third quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 210 shares during the last quarter. KBC Group NV acquired a new position in shares of Nektar Therapeutics in the 1st quarter valued at about $52,000. Headlands Technologies LLC acquired a new position in shares of Nektar Therapeutics in the 2nd quarter valued at about $65,000. State of Wyoming acquired a new position in shares of Nektar Therapeutics in the 1st quarter valued at about $67,000. Finally, Integrated Wealth Concepts LLC purchased a new stake in shares of Nektar Therapeutics during the 1st quarter worth about $68,000. 75.88% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Canaccord Genuity Group started coverage on Nektar Therapeutics in a research report on Wednesday, July 22nd. They issued a “buy” rating and a $153.00 price objective for the company. JPMorgan Chase & Co. started coverage on Nektar Therapeutics in a research report on Friday. They set a “neutral” rating and a $65.00 target price on the stock. Wedbush decreased their price target on Nektar Therapeutics from $95.00 to $80.00 and set a “neutral” rating on the stock in a research note on Monday, May 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Nektar Therapeutics in a report on Tuesday, June 2nd. Finally, Piper Sandler lifted their price target on Nektar Therapeutics from $105.00 to $192.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Nektar Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $141.50.

About Nektar Therapeutics

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.